The main department of described Corporate Investor is located in the Palo Alto. The company was established in North America in United States.
The real fund results show that this Corporate Investor is 0 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this Samsara BioCapital works on 1 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. The important activity for fund was in 2019. The increased amount of exits for fund were in 2019.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Samsara BioCapital, startups are often financed by Alta Partners, Skyline Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Redmile Group, EcoR1 Capital, Cormorant Asset Management. In the next rounds fund is usually obtained by UBS Oncology Impact Fund, Redmile Group, EcoR1 Capital.
The overall number of key employees were 2.
We can highlight the next thriving fund investment areas, such as Clinical Trials, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline ElevateBio, ElevateBio, AlloVir For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
Funds with similar focus
|Sands Brothers Asset Management||United States, New York|
|Nirvana Capital||China, Beijing|
|Otter Media||United States, Santa Monica|
|Frontline Ventures||United Kingdom, London|
|Tennant Capital Partners||United States, Saint Louis|
|Hamilton Ventures LLC||United States, Atlanta|
|Drake Management||United States, Nyack|
|SXSW Interactive||United States, Austin|
|Kloeckner & Co||Germany, Duisburg|
|Hargreave Hale||United Kingdom, London|
|Colour Life Services Group||China, Shenzhen|
|Grupo Picking Pack||-|
|Hallador Investment Advisors||-|
|Huaxin Zhongcheng Investment||China, Guangdong|
|First Check Ventures||-|
|Chelsea Vanguard Fund||-|
|Shenzhen Huijing Tongda Business Consulting||China, Shenzhen|
|Arno Capital||Israel, Ramat Gan|
|$60M||26 Aug 2021||United States, " United States"}|
|$112M||05 Aug 2021||United Kingdom, Oxford|
|$200M||13 Jul 2021||United States, Cambridge|
|$95M||23 Jun 2021||United States, Cambridge|
|$107M||10 Jun 2021||United States, " United States"}|
|$200M||26 May 2021||United States, Wilmington|
|$77M||18 May 2021||United States, Cambridge|
|$115M||13 Apr 2021||United States, " United States"}|
|$525M||15 Mar 2021||United States, Cambridge|
– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.
– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.